IPOB

Ipopema Benefit 3 Fizan WSE:IPOBENE3E Stock Report

Last Price

zł125.00

Market Cap

zł0

7D

0%

1Y

n/a

Updated

21 Jun, 2023

Data

Company Financials

Ipopema Benefit 3 Fizan

WSE:IPOBENE3E Stock Report

Market Cap: zł0

IPOBENE3E Stock Overview

No business description

IPOBENE3E fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Ipopema Benefit 3 Fizan Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Ipopema Benefit 3 Fizan
Historical stock prices
Current Share Pricezł125.00
52 Week Highzł125.00
52 Week Lowzł125.00
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO10.77%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

IPOBENE3EPL Capital MarketsPL Market
7D0%2.7%-1.0%
1Yn/a51.4%25.0%

Return vs Industry: Insufficient data to determine how IPOBENE3E performed against the Polish Capital Markets industry.

Return vs Market: Insufficient data to determine how IPOBENE3E performed against the Polish Market.

Price Volatility

Is IPOBENE3E's price volatile compared to industry and market?
IPOBENE3E volatility
IPOBENE3E Average Weekly Movementn/a
Capital Markets Industry Average Movement5.2%
Market Average Movement5.3%
10% most volatile stocks in PL Market9.5%
10% least volatile stocks in PL Market3.3%

Stable Share Price: IPOBENE3E has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IPOBENE3E's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/an/a

Ipopema Benefit 3 Fizan Fundamentals Summary

How do Ipopema Benefit 3 Fizan's earnings and revenue compare to its market cap?
IPOBENE3E fundamental statistics
Market capn/a
Earnings (TTM)zł0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPOBENE3E income statement (TTM)
Revenuezł0
Cost of Revenuezł0
Gross Profitzł0
Other Expenseszł0
Earningszł0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did IPOBENE3E perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.